Unlearn

Unlearn's mission is to accelerate clinical trials using artificial intelligence.

The company has developed a revolutionary machine learning technology to create digital clones of patients taking part in clinical trials, facilitating shorter, faster studies. Thanks to Unlearn, medicine is moving towards a predictive, preventive and personalized approach.

Based in San Francisco, the company works with pharmaceutical companies, biotechs and university researchers to optimize clinical trials using artificial intelligence methods applied to patient data. Unlearn specializes in the creation of digital twins for diseases such as Alzheimer's and multiple sclerosis.

The aim of creating these digital twins is to reduce the number of patients needed to conduct clinical trials, given that a Phase III clinical trial requires an average of 3,000 participants, while enabling drugs to be tested before they are administered to patients.

The digital twin is not a robot or a 3D body reproduction, but a set of data designed to reflect the characteristics of each human organism as accurately as possible.